93 related articles for article (PubMed ID: 18004569)
1. Imatinib inhibition of fludarabine uptake in T-lymphocytes.
Woodahl EL; Wang J; Heimfeld S; Ren AG; McCune JS
Cancer Chemother Pharmacol; 2008 Sep; 62(4):735-9. PubMed ID: 18004569
[TBL] [Abstract][Full Text] [Related]
2. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
Woodahl EL; Wang J; Heimfeld S; Sandmaier BM; O'Donnell PV; Phillips B; Risler L; Blough DK; McCune JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):391-401. PubMed ID: 18398611
[TBL] [Abstract][Full Text] [Related]
3. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Chen J; Schmitt A; Chen B; Rojewski M; Ringhoffer M; von Harsdorf S; Greiner J; Guillaume P; Döhner H; Bunjes D; Schmitt M
Cancer Immunol Immunother; 2007 Jun; 56(6):849-61. PubMed ID: 17009043
[TBL] [Abstract][Full Text] [Related]
4. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
King KM; Damaraju VL; Vickers MF; Yao SY; Lang T; Tackaberry TE; Mowles DA; Ng AM; Young JD; Cass CE
Mol Pharmacol; 2006 Jan; 69(1):346-53. PubMed ID: 16234483
[TBL] [Abstract][Full Text] [Related]
6. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
7. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.
Chen J; Schmitt A; Giannopoulos K; Chen B; Rojewski M; Döhner H; Bunjes D; Schmitt M
Int J Oncol; 2007 Nov; 31(5):1133-9. PubMed ID: 17912440
[TBL] [Abstract][Full Text] [Related]
8. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Leuk Lymphoma; 1993 May; 10(1-2):49-56. PubMed ID: 8374523
[TBL] [Abstract][Full Text] [Related]
10. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
11. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
12. Intracellular disposition of fludarabine triphosphate in human natural killer cells.
Woodahl EL; Wang J; Heimfeld S; Sandmaier BM; McCune JS
Cancer Chemother Pharmacol; 2009 Apr; 63(5):959-64. PubMed ID: 18781301
[TBL] [Abstract][Full Text] [Related]
13. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Baran Y; Oztekin C; Bassoy EY
Cancer Invest; 2010 Jul; 28(6):623-8. PubMed ID: 20307198
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.
Gamberale R; Galmarini CM; Fernández-Calotti P; Jordheim L; Sánchez-Avalos J; Dumontet C; Geffner J; Giordano M
Biochem Pharmacol; 2003 Dec; 66(11):2185-91. PubMed ID: 14609743
[TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Gao H; Lee BN; Talpaz M; Donato NJ; Cortes JE; Kantarjian HM; Reuben JM
Leukemia; 2005 Nov; 19(11):1905-11. PubMed ID: 16151467
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
20. Modulation of T-effector function by imatinib at the level of cytokine secretion.
Leder C; Ortler S; Seggewiss R; Einsele H; Wiendl H
Exp Hematol; 2007 Aug; 35(8):1266-71. PubMed ID: 17560008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
